The FDA has approved sacubitril/valsartan, an angiotensin-receptor-neprilysin inhibitor, for the treatment of chronic symptomatic heart failure (stage C) in patients with a left ventricular ejection fraction of 35% or less. This article discusses results from a major clinical trial, PARADIGM-HF, and the role of this new drug in heart failure treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.JAA.0000534982.53989.c2 | DOI Listing |
Publication Analysis
Top Keywords
heart failure
12
combined angiotensin
4
angiotensin receptor
4
receptor neprilysin
4
neprilysin inhibition
4
inhibition therapy
4
therapy heart
4
failure fda
4
fda approved
4
approved sacubitril/valsartan
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!